Skip to content
Screener

Other, net at other companies

Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$0+100%
AbbVie logo
AbbVieABBV
$2M-97.0%

Other financials

Income statement

See full
Revenue$3.3B+12.5%
Gross profit$2.8B+11.2%
Operating income$1.2B+8.3%
Net income$1.1B+6.5%
EPS (diluted)$4.31+8.0%

Balance sheet

See full
Cash & equivalents$7.9B+57.6%
Total debt$2.0B+29.5%
Total equity$20.2B+17.9%
Total assets$27.4B+14.1%

Cash flow

See full
Operating cash flow$1.4B+74.4%
CapEx$133.4M+228%
Free cash flow$1.3B+66.4%

Valuation

See full
Market cap$122.68B+24.1%
Enterprise value$116.81B+22.4%
P/E27.9×
P/S9.8×+1.1×

Profitability

See full
Gross margin86%-0.1pp
Operating margin38%
Net margin35%
FCF margin30.4%+20.2pp

Returns & leverage

See full
Return on equity23.5%
Debt / equity0.1×0.0×
Current ratio3.2×+0.7×

Where this comes from

Reported directly by Vertex Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromPaymentsForOtherFinancingActivities.

The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000875320-26-000173
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Issuances of common stock under benefit plans27.016.7
Repurchases of common stock(336.9)(426.1)
Payments in connection with common stock withheld for employee tax obligations(228.5)(270.5)
Other financing activities(0.4)(0.5)
Net cash used in financing activities(538.8)(680.4)
Effect of changes in exchange rates on cash(40.3)30.5
Net increase in cash, cash equivalents and restricted cash417.1113.2
Cash, cash equivalents and restricted cash—beginning of period5,087.84,572.2

Item 1. Financial Statements (unaudited)

FAQ

What is Vertex Pharmaceuticals's other, net?
Vertex Pharmaceuticals (VRTX) reported other, net of -$400K in Q1 2026.
How has Vertex Pharmaceuticals's other, net changed year-over-year?
Vertex Pharmaceuticals's other, net increased by 20.0% year-over-year, from -$500K to -$400K.
What is the long-term trend for Vertex Pharmaceuticals's other, net?
Over 4 years (2021 to 2025), Vertex Pharmaceuticals's other, net has grown at a -10.2% compound annual growth rate (CAGR), from $5.7M to $3.7M.
What does other, net mean?
Includes miscellaneous cash flows related to financing activities that are not categorized as debt issuance, dividends, or share repurchases. This may include changes in non-controlling interests, debt issuance costs, or other unique financing-related transactions. It provides a comprehensive view of non-standard financing cash movements.

Ask your AI about Vertex Pharmaceuticals's other, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude